Drugs / ZIMLOVISERTIB
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05064332 | Oct → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03827668 | Feb → Apr 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03308110 | Sep → Dec 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02936154 | Aug → Oct 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02609139 | Nov 2015 → Feb 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02485769 | Jun 2015 → Apr 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02224651 | Sep 2014 → Jun 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 24 trials · 2 met primary | ||||||
| Phase 2 | NCT04575610 | Nov 2020 → Oct 2021 | COVID-19 | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04413617 | Jul 2020 → Feb 2022 | rheumatoid arthritis | Pfizer | Completed | Mixed |
| Phase 2 | NCT04092452 | Dec 2019 → Jan 2022 | hidradenitis suppurativa | Pfizer | Completed | Met primary |
| Phase 2 | NCT02996500 | Nov 2016 → Aug 2018 | rheumatoid arthritis | Pfizer | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04933799 Comparator | Jan 2021 → Mar 2022 | pneumonia | Giovanni Franchin, M.D, Ph.D | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZIMLOVISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4081711 ↗ |
| Known as | PF-06650833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933799 ↗ |
| Known as | ZIMLOVISERTIB (PF-06650833) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4081711 ↗ |
| Action | Inhibit | “PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).” PMID 31805989 ↗ Dec 2019 |
| Modality | Small molecule | “a highly potent and selective small-molecule inhibitor of interleukin-1-associated kinase 4 (IRAK4)” PMID 34423919 ↗ Nov 2021 |
| Route | Oral | “oral PF-06650833 IR 1 to 6000 mg” PMID 31805989 ↗ Dec 2019 |
| Target | IRAK4 | “PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).” PMID 31805989 ↗ Dec 2019 |